Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-26 @ 5:17 PM
Ignite Modification Date:
2025-12-26 @ 5:17 PM
NCT ID:
NCT03993106
Brief Summary:
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to learn if sEphB4-HSA will decrease the number or size of Kaposi sarcoma lesions in people.
Detailed Description:
sEphB4-HSA will be given through an intravenous infusion (into a vein). Each cycle of sEphB4-HSA will be 28 days (4 weeks). Each cycle of the study drug includes administration of 2 doses of sEphB4-HSA given on Days 1 and 15 of each cycle.
Participants may continue on study protocol as long as their KS is continuing to respond or is clinically stable on study medication.
Patients may come off treatment for the following reasons:
* Disease progression.
* Need for more than 2 dose reductions for toxicity.
* Dose delay more than 28 days.
* Patient withdraws consent.
* Study termination by the Sponsor.
* Participants who are noncompliant with respect to taking drugs, keeping appointments, or having tests required for the evaluation of drug safety and efficacy.
* Participant's condition renders them unacceptable for further treatment in the judgment of the investigator.
Study:
NCT03993106
Study Brief:
Protocol Section:
NCT03993106